Literature DB >> 27401521

Defining secondary progressive multiple sclerosis.

Johannes Lorscheider1, Katherine Buzzard2, Vilija Jokubaitis1, Tim Spelman3, Eva Havrdova4, Dana Horakova4, Maria Trojano5, Guillermo Izquierdo6, Marc Girard7, Pierre Duquette7, Alexandre Prat7, Alessandra Lugaresi8, François Grand'Maison9, Pierre Grammond10, Raymond Hupperts11, Raed Alroughani12, Patrizia Sola13, Cavit Boz14, Eugenio Pucci15, Jeanette Lechner-Scott16, Roberto Bergamaschi17, Celia Oreja-Guevara18, Gerardo Iuliano19, Vincent Van Pesch20, Franco Granella21, Cristina Ramo-Tello22, Daniele Spitaleri23, Thor Petersen24, Mark Slee25, Freek Verheul26, Radek Ampapa27, Maria Pia Amato28, Pamela McCombe29, Steve Vucic30, José Luis Sánchez Menoyo31, Edgardo Cristiano32, Michael H Barnett33, Suzanne Hodgkinson34, Javier Olascoaga35, Maria Laura Saladino36, Orla Gray37, Cameron Shaw38, Fraser Moore39, Helmut Butzkueven40, Tomas Kalincik1.   

Abstract

A number of studies have been conducted with the onset of secondary progressive multiple sclerosis as an inclusion criterion or an outcome of interest. However, a standardized objective definition of secondary progressive multiple sclerosis has been lacking. The aim of this work was to evaluate the accuracy and feasibility of an objective definition for secondary progressive multiple sclerosis, to enable comparability of future research studies. Using MSBase, a large, prospectively acquired, global cohort study, we analysed the accuracy of 576 data-derived onset definitions for secondary progressive multiple sclerosis and first compared these to a consensus opinion of three neurologists. All definitions were then evaluated against 5-year disease outcomes post-assignment of secondary progressive multiple sclerosis: sustained disability, subsequent sustained progression, positive disability trajectory, and accumulation of severe disability. The five best performing definitions were further investigated for their timeliness and overall disability burden. A total of 17 356 patients were analysed. The best definition included a 3-strata progression magnitude in the absence of a relapse, confirmed after 3 months within the leading Functional System and required an Expanded Disability Status Scale step ≥4 and pyramidal score ≥2. It reached an accuracy of 87% compared to the consensus diagnosis. Seventy-eight per cent of the identified patients showed a positive disability trajectory and 70% reached significant disability after 5 years. The time until half of all patients were diagnosed was 32.6 years (95% confidence interval 32-33.6) after disease onset compared with the physicians' diagnosis at 36 (35-39) years. The identified patients experienced a greater disease burden [median annualized area under the disability-time curve 4.7 (quartiles 3.6, 6.0)] versus non-progressive patients [1.8 (1.2, 1.9)]. This objective definition of secondary progressive multiple sclerosis based on the Expanded Disability Status Scale and information about preceding relapses provides a tool for a reproducible, accurate and timely diagnosis that requires a very short confirmation period. If applied broadly, the definition has the potential to strengthen the design and improve comparability of clinical trials and observational studies in secondary progressive multiple sclerosis.
© The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  MSBase; definition; disability; secondary progressive multiple sclerosis; study design

Mesh:

Year:  2016        PMID: 27401521     DOI: 10.1093/brain/aww173

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  78 in total

Review 1.  Treatment decisions in multiple sclerosis - insights from real-world observational studies.

Authors:  Maria Trojano; Mar Tintore; Xavier Montalban; Jan Hillert; Tomas Kalincik; Pietro Iaffaldano; Tim Spelman; Maria Pia Sormani; Helmut Butzkueven
Journal:  Nat Rev Neurol       Date:  2017-01-13       Impact factor: 42.937

Review 2.  Disease-Modifying Treatment in Progressive Multiple Sclerosis.

Authors:  John Robert Ciotti; Anne Haney Cross
Journal:  Curr Treat Options Neurol       Date:  2018-04-07       Impact factor: 3.598

3.  Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.

Authors:  Johannes Lorscheider; Vilija G Jokubaitis; Tim Spelman; Guillermo Izquierdo; Alessandra Lugaresi; Eva Havrdova; Dana Horakova; Maria Trojano; Pierre Duquette; Marc Girard; Alexandre Prat; François Grand'Maison; Pierre Grammond; Eugenio Pucci; Cavit Boz; Patrizia Sola; Diana Ferraro; Daniele Spitaleri; Jeanette Lechner-Scott; Murat Terzi; Vincent Van Pesch; Gerardo Iuliano; Roberto Bergamaschi; Cristina Ramo-Tello; Franco Granella; Celia Oreja-Guevara; Helmut Butzkueven; Tomas Kalincik
Journal:  Neurology       Date:  2017-08-09       Impact factor: 9.910

Review 4.  Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Authors:  A Nandoskar; J Raffel; A S Scalfari; T Friede; R S Nicholas
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

5.  Differentiating societal costs of disability worsening in multiple sclerosis.

Authors:  Nils-Henning Ness; Dirk Schriefer; Rocco Haase; Benjamin Ettle; Christian Cornelissen; Tjalf Ziemssen
Journal:  J Neurol       Date:  2019-12-17       Impact factor: 4.849

6.  Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study.

Authors:  Kelly Fellows Maxwell; Sonia Bhattacharya; Mary Lou Bodziak; Dejan Jakimovski; Jesper Hagemeier; Richard W Browne; Bianca Weinstock-Guttman; Robert Zivadinov; Murali Ramanathan
Journal:  J Lipid Res       Date:  2019-05-13       Impact factor: 5.922

7.  Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  Antonia Valentina Genovese; Jesper Hagemeier; Niels Bergsland; Dejan Jakimovski; Michael G Dwyer; Deepa P Ramasamy; Alexis A Lizarraga; David Hojnacki; Channa Kolb; Bianca Weinstock-Guttman; Robert Zivadinov
Journal:  Radiology       Date:  2019-09-24       Impact factor: 11.105

8.  Prevalence and Risk Factors of Dysphagia in Patients with Multiple Sclerosis.

Authors:  Mahdi Barzegar; Omid Mirmosayeb; Mina Rezaei; Geir Bjørklund; Nasim Nehzat; Alireza Afshari-Safavi; Vahid Shaygannejad
Journal:  Dysphagia       Date:  2021-02-12       Impact factor: 3.438

9.  Network Damage Predicts Clinical Worsening in Multiple Sclerosis: A 6.4-Year Study.

Authors:  Maria A Rocca; Paola Valsasina; Alessandro Meani; Elisabetta Pagani; Claudio Cordani; Chiara Cervellin; Massimo Filippi
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-21

10.  Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.

Authors:  J William L Brown; Alasdair Coles; Dana Horakova; Eva Havrdova; Guillermo Izquierdo; Alexandre Prat; Marc Girard; Pierre Duquette; Maria Trojano; Alessandra Lugaresi; Roberto Bergamaschi; Pierre Grammond; Raed Alroughani; Raymond Hupperts; Pamela McCombe; Vincent Van Pesch; Patrizia Sola; Diana Ferraro; Francois Grand'Maison; Murat Terzi; Jeannette Lechner-Scott; Schlomo Flechter; Mark Slee; Vahid Shaygannejad; Eugenio Pucci; Franco Granella; Vilija Jokubaitis; Mark Willis; Claire Rice; Neil Scolding; Alastair Wilkins; Owen R Pearson; Tjalf Ziemssen; Michael Hutchinson; Katharine Harding; Joanne Jones; Christopher McGuigan; Helmut Butzkueven; Tomas Kalincik; Neil Robertson
Journal:  JAMA       Date:  2019-01-15       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.